Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE
- 1 January 2007
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 36 (6) , 418-423
Abstract
Objective: To characterize dosages and frequencies of infliximab in a publicly financed health‐care system without administrative restrictions on the use of biologics. Methods: Data from the Stockholm TNFα follow‐up registry (STURE) were used. Dosages and frequencies of infliximab were adjusted when clinically indicated. Kaplan–Meier survival function was calculated for maintenance of initial infliximab dosage, initial frequency, and both combined; the influence of baseline characteristics on the adjustments and the effects of these adjustments on clinical outcomes were analysed. All analyses were for patients who continued on therapy only. Results: The 1‐year survival on initial infliximab frequency was 96.3±1.8%, on initial infliximab dose 70.5±4.3%, and on the two combined 68.7±4.3% (cumulative survival estimate ± SE). At 2 years, the corresponding values were 88.1±3.4%, 53.4±5.1%, and 50.3±5.1%, and after 3 years 77.4±4.9%, 45.9±5.4%, and 41.5±5.3%. A higher number of prior disease‐modifying anti‐rheumatic drugs (DMARDs), use of glucocorticoids, and lower baseline swollen joints counts (SJCs) predicted greater likelihood of later adjustments. Efficacy of dosage increases was modest, as reported previously, while frequency increases appeared more efficacious. Conclusion: Infliximab dosages and dosing frequencies are increased frequently in clinical practice: after 3 years, only 42% of patients continued on the original schedule. While frequency increases appear to result in better effect persistence between infusions, the gains from dosage increases are small and may not be better than chance. These data suggest that the total amounts of infliximab needed to obtain satisfactory disease control are greater than the amounts suggested by the original dosing recommendations, and may have bearing on pharmaco‐economic issues pertaining to treatment with infliximab and other therapeutic agents.Keywords
This publication has 15 references indexed in Scilit:
- Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006
- The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo‐controlled trialArthritis & Rheumatism, 2006
- Empirical investigation of experimental design properties of discrete choice experiments in health careHealth Economics, 2005
- Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanerceptAnnals of the Rheumatic Diseases, 2005
- Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trialArthritis & Rheumatism, 2004
- Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effectAnnals of the Rheumatic Diseases, 2004
- Clinical responses to tumor necrosis factor α antagonists do not show a bimodal distribution: Data from the Stockholm Tumor Necrosis Factor α Followup RegistryArthritis & Rheumatism, 2003
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995